265 related articles for article (PubMed ID: 14678293)
21. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
[TBL] [Abstract][Full Text] [Related]
23. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
24. [Pathophysiological significance and clinical utility of circulating osteoprotegerin].
Dovio A; Data V; Angeli A
Ann Ital Med Int; 2004; 19(1):8-19. PubMed ID: 15176704
[TBL] [Abstract][Full Text] [Related]
25. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults.
Jung K; Lein M; Hösslin Kv; Grosse A; Roth S; Possinger K; Lüftner D
Int J Biol Markers; 2002; 17(3):177-81. PubMed ID: 12408468
[TBL] [Abstract][Full Text] [Related]
26. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.
Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E
Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627
[TBL] [Abstract][Full Text] [Related]
27. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.
Rogers A; Eastell R
J Clin Endocrinol Metab; 2005 Nov; 90(11):6323-31. PubMed ID: 16105967
[TBL] [Abstract][Full Text] [Related]
28. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang Zh; Sun LH; Xu MY; Chen JL
Calcif Tissue Int; 2005 Jan; 76(1):1-6. PubMed ID: 15455183
[TBL] [Abstract][Full Text] [Related]
29. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
30. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.
Mazziotti G; Amato G; Sorvillo F; Piscopo M; Rizzo MR; Lalli E; Iride L; Cioffi M; Molinari AM; Paolisso G; Carella C
Eur J Endocrinol; 2006 Mar; 154(3):373-7. PubMed ID: 16498049
[TBL] [Abstract][Full Text] [Related]
31. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
32. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
[TBL] [Abstract][Full Text] [Related]
33. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet.
Fiore CE; Pennisi P; Ferro G; Ximenes B; Privitelli L; Mangiafico RA; Santoro F; Parisi N; Lombardo T
Horm Metab Res; 2006 Jun; 38(6):417-22. PubMed ID: 16823725
[TBL] [Abstract][Full Text] [Related]
34. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients.
Mesquita M; Wittersheim E; Demulder A; Dratwa M; Bergmann P
Adv Perit Dial; 2005; 21():181-4. PubMed ID: 16686314
[TBL] [Abstract][Full Text] [Related]
35. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
[TBL] [Abstract][Full Text] [Related]
36. Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?
Gaudio A; Lasco A; Morabito N; Atteritano M; Vergara C; Catalano A; Fries W; Trifiletti A; Frisina N
J Endocrinol Invest; 2005 Sep; 28(8):677-82. PubMed ID: 16277162
[TBL] [Abstract][Full Text] [Related]
37. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls.
Vanderborght A; Linsen L; Thewissen M; Geusens P; Raus J; Stinissen P
J Rheumatol; 2004 Aug; 31(8):1483-90. PubMed ID: 15290725
[TBL] [Abstract][Full Text] [Related]
38. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice.
Maruyama K; Takada Y; Ray N; Kishimoto Y; Penninger JM; Yasuda H; Matsuo K
J Immunol; 2006 Sep; 177(6):3799-805. PubMed ID: 16951341
[TBL] [Abstract][Full Text] [Related]
39. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
[TBL] [Abstract][Full Text] [Related]
40. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
